



**Commercial/Healthcare Exchange Quantity Limit Criteria**  
*Effective: February 11, 2020*

**Quantity Limit Name:** Secuado

**Products Affected:** Secuado (asenapine) extended-release transdermal patch

**Type of Quantity Limit:**

- FDA maximum
- Usual Daily Frequency
- Split fill
- Other (Please specify): \_\_\_\_\_

**Limits to be applied:**

Secuado (asenapine) extended-release transdermal patches 30 patches per 30 days

**References:**

1. Secuado® transdermal system [prescribing information]. Miami, FL: Noven Therapeutics, LLC; October 2019.

**Policy Revision history**

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	1/17/2020

